Antibody-Drug Conjugates
Antibody-drug conjugates (ADCs) represent a promising therapeutic approach for cancer patients by combining the antigen-targeting specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of chemotherapeutic drugs. In Antibody-Drug Conjugates, expert researchers provide detailed protoc...
Other Authors: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Totowa, NJ
Humana
2013, 2013
|
Edition: | 1st ed. 2013 |
Series: | Methods in Molecular Biology
|
Subjects: | |
Online Access: | |
Collection: | Springer eBooks 2005- - Collection details see MPG.ReNa |
Table of Contents:
- Antibody-Drug Conjugate (ADC) Clinical Pipeline: A Review
- Antibody-Drug Conjugate Target Selection: Critical Factors
- Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy: Internalization and Intracellular Localization
- Antibody-Drug Conjugate Payloads
- Linker Technologies for Antibody-Drug Conjugates
- In Vivo Testing of Drug-Linker Stability
- Pharmacokinetics and ADME Characterizations of Antibody-Drug Conjugates
- Safe Handling of Cytotoxic Compounds in a Biopharmaceutical Environment
- Micro- and Mid-Scale Maleimide-Based Conjugation of Cytotoxic Drugs to Antibody Hinge Region Thiols for Tumor Targeting
- Protocols for Lysine Conjugation
- Engineering THIOMABs for Site-Specific Conjugation of Thiol-Reactive Linkers
- Enzymatic Antibody Modification by Bacterial Transglutaminase
- Formulation Development of Antibody-Drug Conjugates
- Conjugation Process Development and Scale-Up
- Methods for Conjugating Antibodies to Nanocarriers
- Drug-to-Antibody Ratio (DAR) by UV/Vis Spectroscopy
- Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by Hydrophobic Interaction Chromatography and Reversed Phase High Performance Liquid Chromatography
- Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by LC-ESI-MS
- Determination of Charge Heterogeneity and Level of Unconjugated Antibody by Imaged cIEF
- Risk-Based Scientific Approach for Determination of Extractables/Leachables from Biomanufacturing of Antibody-Drug Conjugates (ADCs)